Published in Annu Rev Immunol on January 01, 2005
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis | NCT00393588
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med (2006) 7.87
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med (2007) 6.19
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol (2007) 5.27
Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med (2008) 4.24
MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol (2009) 3.48
Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med (2006) 2.99
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat Med (2012) 2.66
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Retracted Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med (2010) 2.43
Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity (2010) 2.32
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci (2009) 2.24
Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med (2005) 2.18
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol (2012) 2.15
Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2. J Immunol (2014) 2.07
IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol (2011) 2.00
Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis. Proc Natl Acad Sci U S A (2010) 2.00
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 1.98
Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol (2008) 1.93
Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol (2010) 1.91
Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol (2009) 1.83
CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 1.80
Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity (2011) 1.78
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med (2007) 1.77
Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry (2008) 1.77
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology (2009) 1.73
IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci Transl Med (2011) 1.73
Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One (2008) 1.72
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest (2007) 1.67
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest (2008) 1.61
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Cell (2015) 1.60
T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology (2008) 1.59
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother (2011) 1.58
Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One (2013) 1.57
Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol (2010) 1.56
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J Neuroinflammation (2012) 1.52
Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol (2007) 1.51
Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood (2011) 1.50
The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration. J Neurochem (2008) 1.48
Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol (2008) 1.48
The epigenetics of autoimmunity. Cell Mol Immunol (2011) 1.47
Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model. Radiology (2014) 1.46
Akt1 is critical for acute inflammation and histamine-mediated vascular leakage. Proc Natl Acad Sci U S A (2009) 1.46
Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest (2008) 1.44
Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol (2007) 1.43
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest (2006) 1.43
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm (2016) 1.40
Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav Immun (2007) 1.40
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis. PLoS One (2015) 1.39
Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol (2008) 1.34
Systems biology approaches for the study of multiple sclerosis. J Cell Mol Med (2008) 1.33
TCR recognition of peptide/MHC class II complexes and superantigens. Semin Immunol (2007) 1.30
Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity. J Leukoc Biol (2009) 1.28
Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A (2005) 1.28
The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist (2010) 1.28
Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A (2010) 1.26
Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol (2011) 1.26
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J Clin Invest (2006) 1.25
Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol (2013) 1.25
Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med (2006) 1.25
MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci U S A (2012) 1.24
A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One (2008) 1.24
Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2009) 1.23
Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res (2009) 1.22
The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol (2010) 1.21
Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol (2013) 1.21
Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS (2011) 1.21
What went wrong? The flawed concept of cerebrospinal venous insufficiency. J Cereb Blood Flow Metab (2013) 1.19
Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem (2007) 1.19
Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev (2009) 1.19
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus. J Exp Med (2006) 1.17
Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol (2007) 1.17
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2010) 1.16
The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J (2013) 1.16
Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells. Nat Neurosci (2013) 1.16
Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One (2008) 1.14
Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol (2007) 1.11
Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J Autoimmun (2010) 1.11
Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad Sci U S A (2006) 1.11
p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis. Am J Pathol (2007) 1.10
Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci U S A (2009) 1.10
TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain (2009) 1.09
MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J Neuroimmunol (2007) 1.09
Teriflunomide and its mechanism of action in multiple sclerosis. Drugs (2014) 1.08
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1. Am J Pathol (2008) 1.08
Autophagy, inflammation and neurodegenerative disease. Eur J Neurosci (2010) 1.08
Gammadelta T cells in EAE: early trafficking events and cytokine requirements. Eur J Immunol (2009) 1.07
Recognition of self-peptide-MHC complexes by autoimmune T-cell receptors. Trends Biochem Sci (2007) 1.07
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain (2012) 1.06
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 4.87
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci (2002) 1.99
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 1.98
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Development of biomarkers in multiple sclerosis. Brain (2004) 1.78
Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One (2008) 1.72
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain (2003) 1.71
The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One (2012) 1.67
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet (2003) 1.59
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol (2004) 1.56
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. Eur J Immunol (2008) 1.51
Clinical nurse specialists and the practice of community nurses. J Adv Nurs (2006) 1.42
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med (2008) 1.33
JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol (2013) 1.29
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain (2011) 1.22
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain (2010) 1.21
T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol (2012) 1.21
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol (2011) 1.17
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol (2009) 1.16
A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol Immunol (2004) 1.15
Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol (2007) 1.11
The value of animal models for drug development in multiple sclerosis. Brain (2006) 1.11
Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol (2004) 1.07
Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol (2011) 1.07
Application of support vector machines for T-cell epitopes prediction. Bioinformatics (2003) 1.05
Infectious causes of multiple sclerosis. Lancet Neurol (2006) 1.04
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol (2012) 1.01
Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. J Infect Dis (2006) 0.98
Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol (2008) 0.95
High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete Borrelia turicatae. J Neuropathol Exp Neurol (2007) 0.95
Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae. Am J Pathol (2007) 0.95
Training-dependent plasticity in patients with multiple sclerosis. Brain (2004) 0.94
Spotlight on anti-CD25: daclizumab in MS. Int MS J (2008) 0.94
Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis. Infect Immun (2006) 0.92
Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog (2005) 0.92
HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol (2005) 0.92
TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol (2007) 0.91
Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. J Immunol (2010) 0.91
Genomics in multiple sclerosis--current state and future directions. J Neuroimmunol (2007) 0.90
Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res (2013) 0.89
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol (2003) 0.89
Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr Treat Options Neurol (2013) 0.89
Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol (2007) 0.89
Borrelia burgdorferi Induces TLR1 and TLR2 in human microglia and peripheral blood monocytes but differentially regulates HLA-class II expression. J Neuropathol Exp Neurol (2006) 0.89
Antigen-specific therapies in MS - Current concepts and novel approaches. J Neurol Sci (2008) 0.88
Kinematic specificity of cortical reorganization associated with motor training. Neuroimage (2004) 0.88
Nogo receptor is involved in the adhesion of dendritic cells to myelin. J Neuroinflammation (2011) 0.87
T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol (2013) 0.87
Use of combinatorial peptide libraries for T-cell epitope mapping. Methods (2003) 0.87
TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection. J Immunol (2012) 0.86
CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. Glia (2005) 0.86
High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol (2005) 0.86
Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient. J Neurovirol (2002) 0.86
Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. Curr Opin Neurol (2003) 0.86
Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer Treat Rev (2013) 0.85
Multiple sclerosis: closing in on an oral treatment. Nature (2010) 0.85
The immunopathogenesis of multiple sclerosis. J Rehabil Res Dev (2002) 0.85
Autoantigens act as tissue-specific chemoattractants. J Leukoc Biol (2005) 0.85
Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol (2006) 0.85
Molecular mimicry in multiple sclerosis. Autoimmunity (2006) 0.85
Clinically isolated neurosarcoidosis: a recommended diagnostic path. Eur Neurol (2014) 0.83
Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice. J Exp Med (2004) 0.83
Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis. J Neuroimmunol (2005) 0.82
Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients. J Neuroimmunol (2013) 0.82
Antigen-specific therapies in multiple sclerosis. Int Rev Immunol (2005) 0.82
Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis. PLoS One (2011) 0.82
Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis. Lancet Neurol (2008) 0.81
The initiation of the autoimmune response in multiple sclerosis. Clin Neurol Neurosurg (2004) 0.81
Antigen-specific tolerization approaches in multiple sclerosis. Expert Opin Investig Drugs (2013) 0.81
Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLoS One (2012) 0.80
Findings on T cell specificity revealed by synthetic combinatorial libraries. J Immunol Methods (2002) 0.80
HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. Brain (2013) 0.80
Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol (2005) 0.79
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis. Mult Scler (2009) 0.79
Combining positional scanning peptide libraries, HLA-DR transfectants and bioinformatics to dissect the epitope spectrum of HLA class II cross-restricted CD4+ T cell clones. J Immunol Methods (2009) 0.79
HLA class I: friend and foe of multiple sclerosis. Nat Med (2008) 0.79
T-cell epitope prediction with combinatorial peptide libraries. J Comput Biol (2002) 0.79
Stem cell transplantation in multiple sclerosis. J Neurol (2008) 0.78
Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. Autoimmunity (2013) 0.78
Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. J Immunol (2012) 0.78
Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Mult Scler (2011) 0.78
Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling. Eur J Immunol (2014) 0.77
Limited repertoire of HLA-DRB1*0401-restricted MBP111-129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential. J Neuroimmunol (2004) 0.77
Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. J Neuroimmunol (2006) 0.77
When T cells recognize a pattern, they might cause trouble. Curr Opin Immunol (2006) 0.76